News Release

HemogloBind™ Used in Study of Erythrocytotoxicity

MONMOUTH JUNCTION, NJ, March 24, 2023 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of HemogloBind™, to remove Hemoglobin interference, in a study investigating erythrocytotoxicity from silica nanoparticles (SiNPs).

The citation is:

Zhan, Jing, et al. "Silica nanoparticles trigger phosphatidylserine exposure in red blood cells and induce thrombosis risk." Environmental Pollution (2023): 121591.

Silica nanoparticles (SiNPs) have attracted increasing attention for their health effects due to the increased risk of exposure to human bodies via diverse routes. Considering that SiNPs enter the circulatory system and inevitably encounter red blood cells (RBCs), it is necessary to investigate their risk of causing erythrocytotoxicity. In this study, three sizes of SiNPs (SiNP-60, SiNP-120, and SiNP-200) were tested for their effects on mouse RBCs. The results showed that SiNPs could induce hemolysis, morphological changes, and phosphatidylserine (PS) exposure in RBCs in a particulate size-related manner. Further investigations on the underlying mechanism indicated that SiNP-60 exposure increased intracellular reactive oxidative species (ROS) generation and subsequently caused the phosphorylation of p38 and ERK1/2 in RBCs. For Western blot analysis, the article states “To evaluate the phosphorylated ERK1/2 and total ERK1/2, the protein samples from different groups were mixed with 100 μL of HemogloBind™ suspension (Biotech Support Group LLC, NJ, USA) that could specifically adsorb hemoglobin”. The report findings revealed the procoagulant and prothrombotic effects of SiNPs through the regulation of PS externalization in RBCs, and may be of great help in bridging the knowledge gap on the potential cardiovascular hazards of particulate silica from both artificial and naturally occurring origins.

“All of our products are species agnostic, as they not derived from immuno-affinity, so they work for all species to the best of our knowledge. Here is another example of the versatility of HemogloBind™, as it is used here to clear interference in Western blot analysis from mouse RBCs.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Click here for more information on HemogloBind™

Click here for more information on all of our Hemoglobin Removal products

Keywords: Silica nanoparticles, Erythrocytotoxicity, Hemoglobin Removal, HemogloBind™, phosphorylated ERK1/2

About Biotech Support Group LLC

Converging with technological disruptions forthcoming in healthcare, Biotech Support Group continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com